These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 16637795)

  • 1. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibandronate: a new oral bisphosphonate for postmenopausal osteoporosis.
    Guay DR
    Consult Pharm; 2005 Dec; 20(12):1036-55. PubMed ID: 16548678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
    Heidenreich A; Ohlmann CH
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.
    Miller PD; Ward P; Pfister T; Leigh C; Body JJ
    Clin Exp Rheumatol; 2008; 26(6):1125-33. PubMed ID: 19210886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY
    Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
    Bauss F; Bergström B
    Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
    Pecherstorfer M; Diel IJ
    Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibandronate: a clinical pharmacological and pharmacokinetic update.
    Barrett J; Worth E; Bauss F; Epstein S
    J Clin Pharmacol; 2004 Sep; 44(9):951-65. PubMed ID: 15317823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibandronate.
    Dooley M; Balfour JA
    Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.
    Ringe JD; Dorst A; Faber H
    Osteoporos Int; 2005 Dec; 16(12):2063-8. PubMed ID: 16228105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.